In addition to the SUS, TRU will also more than likely over the next years or so ramp up Device manufacturing to at least 200 or 300 (probably more) devices per year that on its own (without even counting the SUS income which would keep increasing) would have an income of something in the range of $2 - $3 million thus in addition to the SUS income creating an additional yearly $800,000 to $1,200,000 in profit,
looks to me like they are slightly ahead of targets but I think the fundamentals ( I see company well positioned with trial results and some big Hospital orders to follow)
I believe the Truscreen Device ( and the SUS ) sales are all soon going to rapidly increase.
the question you need to ask is if you want to take the risk buy at around 6 cents share or wait until more information flows in and pay say 3 x the currant price so cutting your long term profit by 3 fold?
I could be wrong but I believe I can see Lots of factors coming nicely together that are pointing to Truscreen being successful
For an in depth review....
https://truscreen.com/news/pitt-street-research-report-nzxtru/regards
fp
